Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Invion (ASX:IVX) Surges 20% on Non-Dilutive Funding for Cancer Program

Invion Secures Non-Dilutive Backing to Advance Cancer Therapy Invion (ASX:IVX) saw a sharp rerating today, with the share price rising 20% following the announcement of potential non-dilutive funding that meaningfully changes the near-term risk profile of the business. Rather than issuing new shares to advance its oesophageal cancer program, Hanlim Pharm will fund the required preclinical…

ByCharlie YouldenDecember 23, 2025

Is Pro Medicus (ASX:PME) a Buy After the 34% Pullback?

Pro Medicus slips, growth momentum remains Pro Medicus (ASX: PME) has dropped approximately 34% from its record high of A$336 in July 2025 and now trades near A$222. Investors are asking if Australia’s top-performing stock has finally slowed down. For context, this company has delivered 54,000 per cent returns over 15 years, making it a…

ByUjjwal MaheshwariDecember 23, 2025

Regis Healthcare (ASX:REG) Drops Below $7.20 on CEO Exit: A Buying Opportunity?

Regis Healthcare CEO Exit: What Investors Watch Next Regis Healthcare (ASX: REG) shares fell 2.6% to A$7.13 after CEO Dr Linda Mellors announced her resignation to pursue a career opportunity in a different industry. The departure ends a six-year tenure that transformed Regis Healthcare from a struggling business into one of the ASX's best-performing healthcare…

ByUjjwal MaheshwariDecember 23, 2025

Is Telix Pharmaceuticals (ASX:TLX) Now Undervalued With Phase 3 China Clinical Success?

Why Telix Pharmaceuticals Pullback Could Be a Second Chance Telix Pharmaceuticals (ASX:TLX) has faced a challenging year, particularly for a company that previously delivered consistently strong growth. Disclosure issues and delays around FDA progress for its brain cancer imaging asset have clearly weighed on sentiment and reset near term expectations. As a result, the stock…

ByCharlie YouldenDecember 22, 2025

Telix Pharmaceuticals (ASX:TLX) Down 55% Amid Lawsuit: Is It Time to Buy or Sell?

Telix Pharmaceuticals (ASX: TLX) has been crushed in 2025. The stock has fallen roughly 55% from its February high of A$32 to around A$12.50 today. The damage came from three blows: an SEC subpoena in July, an FDA Complete Response Letter (CRL) in August, and now a US class action lawsuit. We believe this selloff…

ByUjjwal MaheshwariDecember 17, 2025

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Neuren Pharmaceuticals (ASX: NEU) rose 2.5% yesterday after the US FDA approved DAYBUE STIX, a new powder formulation of its Rett syndrome treatment. The stock has surged 47% over the past year, significantly outperforming the broader ASX, and now trades at a market capitalisation of around AUD 2.55 billion. For investors watching the healthcare space,…

ByUjjwal MaheshwariDecember 16, 2025

Medibank Private shares have recovered the losses after the cyber breach 2 years ago, but what’s next?

Medibank Private shares took a big hit nearly 3 years ago due to the infamous cyber breach. Investors who chose to buy the dip and have held ever since have done quite well - shares rallied 80% in the following 3 years. But shares have fallen over 12% since August, when it released its FY25 results.…

ByNick SundichDecember 11, 2025

Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?

Rhythm Biosciences (ASX: RHY) may finally be turning the corner. The company has secured NHS expertise to support its ColoSTAT bowel cancer blood test launch in the UK, while a separate deal with Catch Bio expands its geneType platform across the United States. For a stock trading at just A$25 to A$30 million market cap,…

ByUjjwal MaheshwariDecember 11, 2025

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Orthocell (ASX: OCC) jumped 7% to A$1.09 on Wednesday after announcing its first commercial sales of Remplir in Hong Kong. The sales, made through distributor MontsMed, follow last month's first surgical case in the region and a strong debut at the Hong Kong Orthopaedic Association's 45th Annual Congress. For investors, this milestone shows the company…

ByUjjwal MaheshwariDecember 11, 2025

4DMedical’s Growth Story Gains Airflow in the US Market

4DMedical Finds Its Rhythm 4DMedical (ASX:4DX) climbed 9% today as the company continues to build strong commercial momentum with its CT:VQ lung imaging technology. Following FDA clearance in September, 4DMedical’s entry into the US market is beginning to gain real traction. The latest partnership with the University of Miami adds another major institution to its…

ByCharlie YouldenDecember 10, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Invion (ASX:IVX) Surges 20% on Non-Dilutive Funding for Cancer Program

Is Pro Medicus (ASX:PME) a Buy After the 34% Pullback?

Regis Healthcare (ASX:REG) Drops Below $7.20 on CEO Exit: A Buying Opportunity?

Is Telix Pharmaceuticals (ASX:TLX) Now Undervalued With Phase 3 China Clinical Success?

Telix Pharmaceuticals (ASX:TLX) Down 55% Amid Lawsuit: Is It Time to Buy or Sell?

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Medibank Private shares have recovered the losses after the cyber breach 2 years ago, but what’s next?

Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

4DMedical’s Growth Story Gains Airflow in the US Market

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here